BiogenIDEC

Biogen Idec is pharmaceutical and biotechnology company headquartered in Cambridge, Massachusetts. It was created by the 2003 merger of Biogen, Inc., founded in 1978, and IDEC Pharmaceuticals, founded in 1985. Company products include the best seller multiple sclerosis drug Avonex. Other products include Rituxan, a monoclonal antibody developed with Genentech to treat B-cell non-Hodgkin's lymphoma (NHL), rheumatoid arthritis and multiple sclerosis. Also the Crohn's disease drug Tysabri and Fumaderm, a psoriasis drug marketed in Germany. Biogen Idec has customers in over 90 countries.

In the fiscal year ending in December of 2009, Biogen reported sales of approximately $4.38 billion dollars and had 4,750 employees.

Animal testing
Biogen Idec does animal testing.

Facility information, progress reports & USDA-APHIS reports
For links to copies of this facility's U.S. Department of Agriculture-Animal Plant Health Inspection (APHIS) reports, other information and links, see also Research Facilities: Biogen Idec, Inc., San Diego, CA.

USDA AWA reports
As of May 26, 2009, the USDA began posting all inspection reports for animal breeders, dealers, exhibitors, handlers, research facilities and animal carriers by state. See also USDA Animal Welfare Inspection Reports.

Key executives

 * Bruce Ross - Chairman
 * James Mullen - President, CEO & director
 * Robert Hamm - COO

Board

 * Bruce R. Ross, Chairman of Biogen Idec
 * James C. Mullen, Chief Executive Officer of Biogen Idec
 * Lawrence C. Best, Director
 * Marijn E. Dekkers, Ph.D., Director
 * Alan B. Glassberg, M.D., Director
 * Thomas F. Keller, Director
 * Robert W. Pangia, Director
 * Cecil B. Pickett, Ph.D., Director
 * Lynn Schenk, Director
 * Philip A. Sharp, Ph.D., Director
 * William D. Young, Director

Contact
Biogen Idec 14 Cambridge Center Cambridge, MA 02142 United States

Phone: 617-679-2000

Fax: 617-679-2617

Web address: http://www.biogenidec.com

SourceWatch articles

 * Alan K. Simpson - Former Director
 * Animal testing
 * Pharmaceutical industry
 * War on Cancer